Matrix (breast implant)

2024: Implant Release

On August 29, 2024, the American company Melodi Health announced the release of the absorbable Matrix implant for patients diagnosed with malignant breast lesions. The product is intended for women undergoing breast reconstruction after mastectomy.

According to the World Health Organization (WHO), in 2022, breast cancer was detected in 2.3 million women and caused 670 thousand deaths worldwide. Breast malignancies occur in patients of any age after reaching puberty. About half of all cases of such tumors occur in women not exposed to any specific risk factors except sex and age. With surgery, only a malignant tumor (the so-called lumpectomy) or the entire mammary gland (mastectomy) can be removed. Lymph nodes may also be removed to prevent the tumor from spreading.

Melodi Health

As noted by Melodi Health, one of the four breast reconstruction procedures after mastectomy is accompanied by complications. In every tenth case, repeated surgery is required or negative effects due to infection may be observed. The Matrix implant is designed to solve problems. This synthetic scaffold, after installation, gradually releases antibiotics. Thanks to the macroporous structure, the product promotes tissue germination and expansion. In this case, the implant resolves over time, due to which intervention is not required to remove it.

Melodi Health reported raising $10.75 million in funding through the Series A round. Investors included HM Venture Partners, Engage Venture Partners, Southeast Minnesota Capital Fund and Three Bridges Private Capital. The money will go to further product development.^[1]

Notes